Approval · Notice of Compliance 13241 · 2012
RASILEZ: Notice of Compliance 13241
Issued April 26, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13241
- Date
- April 26, 2012
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Removal of the indication for concomitant use of Rasilez with angiotensin converting enzyme inhibitors and Angiotensin ii AT1 receptor blockers
- Therapeutic class
- Renin Inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RASILEZ | Not yet assigned | — |
Medicinal ingredients
- ALISKIREN FUMARATE 150 MG per TAB
- ALISKIREN FUMARATE 300 MG per TAB